Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma.

PubWeight™: 2.66‹?› | Rank: Top 1%

🔗 View Article (PMC 3081971)

Published in Gastroenterology on February 12, 2011

Authors

Augusto Villanueva1, Yujin Hoshida, Carlo Battiston, Victoria Tovar, Daniela Sia, Clara Alsinet, Helena Cornella, Arthur Liberzon, Masahiro Kobayashi, Hiromitsu Kumada, Swan N Thung, Jordi Bruix, Philippa Newell, Craig April, Jian-Bing Fan, Sasan Roayaie, Vincenzo Mazzaferro, Myron E Schwartz, Josep M Llovet

Author Affiliations

1: HCC Translational Research Laboratory, Barcelona-Clinic Liver Cancer Group, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Liver Unit, Hospital Clinic, Barcelona, Spain.

Articles citing this

Hepatocellular carcinoma: clinical frontiers and perspectives. Gut (2014) 5.79

Targeted therapies for hepatocellular carcinoma. Gastroenterology (2011) 2.85

Integration of tumour and viral genomic characterizations in HBV-related hepatocellular carcinomas. Gut (2014) 2.19

A genomic and clinical prognostic index for hepatitis C-related early-stage cirrhosis that predicts clinical deterioration. Gut (2014) 1.84

Notch signaling is activated in human hepatocellular carcinoma and induces tumor formation in mice. Gastroenterology (2012) 1.71

Medical therapies for hepatocellular carcinoma: a critical view of the evidence. Nat Rev Gastroenterol Hepatol (2012) 1.57

UHRF1 overexpression drives DNA hypomethylation and hepatocellular carcinoma. Cancer Cell (2014) 1.50

The Singapore Liver Cancer Recurrence (SLICER) Score for relapse prediction in patients with surgically resected hepatocellular carcinoma. PLoS One (2015) 1.46

Role of epigenetic aberrations in the development and progression of human hepatocellular carcinoma. Cancer Lett (2012) 1.36

Advances in targeted therapies for hepatocellular carcinoma in the genomic era. Nat Rev Clin Oncol (2015) 1.33

Genome-wide methylation analysis and epigenetic unmasking identify tumor suppressor genes in hepatocellular carcinoma. Gastroenterology (2013) 1.26

Inflammation-related factors predicting prognosis of gastric cancer. World J Gastroenterol (2014) 1.09

Prognostic factors for hepatocellular carcinoma recurrence. World J Gastroenterol (2014) 1.06

Liver cancer: Approaching a personalized care. J Hepatol (2015) 1.05

Transcriptome profiling of archived sectioned formalin-fixed paraffin-embedded (AS-FFPE) tissue for disease classification. PLoS One (2014) 1.01

comoR: a software for disease comorbidity risk assessment. J Clin Bioinforma (2014) 1.01

Multidisciplinary Canadian consensus recommendations for the management and treatment of hepatocellular carcinoma. Curr Oncol (2011) 1.00

Expression profiling of archival tumors for long-term health studies. Clin Cancer Res (2012) 0.96

Gene expression analysis in RA: towards personalized medicine. Pharmacogenomics J (2014) 0.96

Global gene expression profiling reveals SPINK1 as a potential hepatocellular carcinoma marker. PLoS One (2013) 0.95

Prognostic biomarkers for prediction of recurrence of hepatocellular carcinoma: current status and future prospects. World J Gastroenterol (2014) 0.93

Differential combinatorial regulatory network analysis related to venous metastasis of hepatocellular carcinoma. BMC Genomics (2012) 0.92

Transcriptional dissection of pancreatic tumors engrafted in mice. Genome Med (2014) 0.92

MicroRNA-29a-5p is a novel predictor for early recurrence of hepatitis B virus-related hepatocellular carcinoma after surgical resection. PLoS One (2012) 0.91

Current biomarkers for hepatocellular carcinoma: Surveillance, diagnosis and prediction of prognosis. World J Hepatol (2015) 0.90

The changing landscape of hepatocellular carcinoma: etiology, genetics, and therapy. Am J Pathol (2013) 0.89

Quality assessment metrics for whole genome gene expression profiling of paraffin embedded samples. BMC Res Notes (2013) 0.85

Liver resection for young patients with large hepatocellular carcinoma: a single center experience from China. World J Surg Oncol (2014) 0.85

Management of small hepatocellular carcinoma in cirrhosis: focus on portal hypertension. World J Gastroenterol (2013) 0.84

Molecular classification of hepatocellular carcinoma: potential therapeutic implications. Hepat Oncol (2015) 0.84

Liver transplantation for hepatocellular carcinoma: role of inflammatory and immunological state on recurrence and prognosis. World J Gastroenterol (2013) 0.83

A re-emerging marker for prognosis in hepatocellular carcinoma: the add-value of fishing c-myc gene for early relapse. PLoS One (2013) 0.82

Novel biomarkers for hepatocellular carcinoma surveillance: has the future arrived? Hepatobiliary Surg Nutr (2014) 0.80

Hepatocellular tumors: immunohistochemical analyses for classification and prognostication. Chin J Cancer Res (2011) 0.80

ALDH3A1 is overexpressed in a subset of hepatocellular carcinoma characterised by activation of the Wnt/ß-catenin pathway. Virchows Arch (2013) 0.79

Novel insights in the genetics of HCC recurrence and advances in transcriptomic data integration. J Hepatol (2011) 0.79

Specific genomic and transcriptomic aberrations in tumors induced by partial hepatectomy of a chronically inflamed murine liver. Oncotarget (2014) 0.78

Monocarboxylate transporter 4 predicts poor prognosis in hepatocellular carcinoma and is associated with cell proliferation and migration. J Cancer Res Clin Oncol (2014) 0.78

Cancer stem cells in hepatocellular carcinoma - an immunohistochemical study with histopathological association. Indian J Med Res (2015) 0.78

Network features suggest new hepatocellular carcinoma treatment strategies. BMC Syst Biol (2014) 0.78

iSubgraph: integrative genomics for subgroup discovery in hepatocellular carcinoma using graph mining and mixture models. PLoS One (2013) 0.78

Prognostic gene signatures for hepatocellular carcinoma: what are we measuring? Ann Surg Oncol (2013) 0.78

Positive immunostaining of Sal-like protein 4 is associated with poor patient survival outcome in the large and undifferentiated Korean hepatocellular carcinoma. Ann Surg Treat Res (2016) 0.78

Next generation sequencing, inter-tumor heterogeneity and prognosis of hepatitis B related hepatocellular carcinoma. Chin J Cancer Res (2014) 0.77

Correlation of APOBEC3 in tumor tissues with clinico-pathological features and survival from hepatocellular carcinoma after curative hepatectomy. Int J Clin Exp Med (2015) 0.77

Challenges of incorporating gene expression data to predict HCC prognosis in the age of systems biology. World J Gastroenterol (2012) 0.77

Characterization of diethylnitrosamine-induced liver carcinogenesis in Syrian golden hamsters. Exp Ther Med (2011) 0.77

Hepatocellular carcinoma: Consensus, controversies and future directions. A report from the Canadian Association for the Study of the Liver Hepatocellular Carcinoma Meeting. Can J Gastroenterol Hepatol (2015) 0.77

ABCB6 mRNA and DNA methylation levels serve as useful biomarkers for prediction of early intrahepatic recurrence of hepatitis C virus-related hepatocellular carcinoma. Int J Oncol (2013) 0.76

A Global Risk Score (GRS) to Simultaneously Predict Early and Late Tumor Recurrence Risk after Resection of Hepatocellular Carcinoma. Transl Oncol (2016) 0.75

GLUT1 and ASCT2 as Predictors for Prognosis of Hepatocellular Carcinoma. PLoS One (2016) 0.75

Prophylactic liver transplantation for high-risk recurrent hepatocellular carcinoma. World J Hepatol (2016) 0.75

High expression of micro RNA-135A in hepatocellular carcinoma is associated with recurrence within 12 months after resection. BMC Cancer (2017) 0.75

Novel Pretreatment Scoring Incorporating C-reactive Protein to Predict Overall Survival in Advanced Hepatocellular Carcinoma with Sorafenib Treatment. Liver Cancer (2016) 0.75

Biphasic and Stage-Associated Expression of CPEB4 in Hepatocellular Carcinoma. PLoS One (2016) 0.75

Comparative analysis of hepatocellular carcinoma and cirrhosis gene expression profiles. Mol Med Rep (2016) 0.75

Hepatocellular carcinoma: can circulating tumor cells and radiogenomics deliver personalized care? Am J Clin Oncol (2015) 0.75

SH3-domain binding protein 1 in the tumor microenvironment promotes hepatocellular carcinoma metastasis through WAVE2 pathway. Oncotarget (2016) 0.75

Overexpression of Leucine-Rich Repeat-Containing G Protein-Coupled Receptor 5 (LGR5) Represents a Typical Wnt/β-Catenin Pathway-Activated Hepatocellular Carcinoma. Liver Cancer (2014) 0.75

A Transcriptomic Signature of Mouse Liver Progenitor Cells. Stem Cells Int (2016) 0.75

Decrease of RBM4 indicates poor prognosis in patients with hepatocellular carcinoma after hepatectomy. Onco Targets Ther (2017) 0.75

Prediction and prophylaxis of hepatocellular carcinoma occurrence and postoperative recurrence in chronic hepatitis B virus-infected subjects. World J Gastroenterol (2016) 0.75

Immunohistochemistry panel segregates molecular types of hepatocellular carcinoma in Brazilian autopsy cases. World J Gastroenterol (2016) 0.75

Imaging-based surrogate markers of transcriptome subclasses and signatures in hepatocellular carcinoma: preliminary results. Eur Radiol (2017) 0.75

Liver Cancer: Molecular Characterization, Clonal Evolution and Cancer Stem Cells. Cancers (Basel) (2017) 0.75

A Surgical Perspective on Targeted Therapy of Hepatocellular Carcinoma. Diseases (2015) 0.75

A new semi-supervised learning model combined with Cox and SP-AFT models in cancer survival analysis. Sci Rep (2017) 0.75

Conditional Survival Analysis Demonstrates that Recurrence Risk of Surgically Treated Hepatocellular Carcinoma Evolves with Time. J Gastrointest Surg (2017) 0.75

Articles cited by this

Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A (2005) 167.46

Cancer statistics, 2009. CA Cancer J Clin (2009) 83.57

Sorafenib in advanced hepatocellular carcinoma. N Engl J Med (2008) 54.30

Hepatocellular carcinoma. Lancet (2003) 22.54

More powerful procedures for multiple significance testing. Stat Med (1990) 17.12

Concordance among gene-expression-based predictors for breast cancer. N Engl J Med (2006) 13.50

Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst (2008) 11.27

Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst (2005) 9.38

Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med (2008) 9.20

Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology (2004) 6.98

A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Nat Med (2006) 6.31

Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol (2003) 6.14

Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol (2008) 5.93

Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning. Nat Med (2003) 5.45

Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology (2007) 4.73

Resection and liver transplantation for hepatocellular carcinoma. Semin Liver Dis (2005) 4.51

Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. Cancer Res (2008) 4.35

Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. Cancer Cell (2006) 4.33

Enabling personalized cancer medicine through analysis of gene-expression patterns. Nature (2008) 4.24

EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma. Cancer Res (2008) 4.17

Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology (2008) 4.03

Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort. Hepatology (2005) 3.95

Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype. J Clin Invest (2006) 3.95

Oligonucleotide microarray for prediction of early intrahepatic recurrence of hepatocellular carcinoma after curative resection. Lancet (2003) 3.93

Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Res (2009) 3.77

Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study. Lancet Oncol (2009) 2.53

Clinicopathological study on cholangiolocellular carcinoma suggesting hepatic progenitor cell origin. Hepatology (2008) 2.40

Relation between resistance of Philadelphia-chromosome-positive acute lymphoblastic leukaemia to the tyrosine kinase inhibitor STI571 and gene-expression profiles: a gene-expression study. Lancet (2002) 2.33

Molecular-based prediction of early recurrence in hepatocellular carcinoma. J Hepatol (2004) 2.10

Transforming growth factor-beta gene expression signature in mouse hepatocytes predicts clinical outcome in human cancer. Hepatology (2008) 2.04

Progenitor-derived hepatocellular carcinoma model in the rat. Hepatology (2010) 2.03

Identification of a cholangiocarcinoma-like gene expression trait in hepatocellular carcinoma. Cancer Res (2010) 1.82

Hepatic stem-like phenotype and interplay of Wnt/beta-catenin and Myc signaling in aggressive childhood liver cancer. Cancer Cell (2008) 1.70

Nearest template prediction: a single-sample-based flexible class prediction with confidence assessment. PLoS One (2010) 1.65

New strategies in hepatocellular carcinoma: genomic prognostic markers. Clin Cancer Res (2010) 1.46

Gene expression-based recurrence prediction of hepatitis B virus-related human hepatocellular carcinoma. Clin Cancer Res (2008) 1.41

Consistency of Random Survival Forests. Stat Probab Lett (2010) 1.29

Specific gene-expression profiles of noncancerous liver tissue predict the risk for multicentric occurrence of hepatocellular carcinoma in hepatitis C virus-positive patients. Ann Surg Oncol (2006) 1.20

Molecular prediction of early recurrence after resection of hepatocellular carcinoma. Eur J Cancer (2009) 0.96

Articles by these authors

A second generation human haplotype map of over 3.1 million SNPs. Nature (2007) 85.39

Sorafenib in advanced hepatocellular carcinoma. N Engl J Med (2008) 54.30

Hepatocellular carcinoma. Lancet (2003) 22.54

Hepatocellular carcinoma. Lancet (2012) 18.09

Genome-wide detection and characterization of positive selection in human populations. Nature (2007) 17.27

Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet (2002) 12.16

Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology (2003) 11.55

Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst (2008) 11.27

High density DNA methylation array with single CpG site resolution. Genomics (2011) 10.35

Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis (2010) 9.73

Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med (2008) 9.20

High-throughput DNA methylation profiling using universal bead arrays. Genome Res (2006) 8.05

Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology (2002) 6.92

Characterization of the single-cell transcriptional landscape by highly multiplex RNA-seq. Genome Res (2011) 6.90

Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. Hepatology (2008) 6.75

Lin28 promotes transformation and is associated with advanced human malignancies. Nat Genet (2009) 6.35

Molecular targeted therapies in hepatocellular carcinoma. Hepatology (2008) 6.16

Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol (2008) 5.93

Current strategy for staging and treatment: the BCLC update and future prospects. Semin Liver Dis (2010) 5.85

Hepatocellular carcinoma: clinical frontiers and perspectives. Gut (2014) 5.79

Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther (2008) 5.78

The international position on laparoscopic liver surgery: The Louisville Statement, 2008. Ann Surg (2009) 5.33

A genome-wide association study identifies variants in the HLA-DP locus associated with chronic hepatitis B in Asians. Nat Genet (2009) 5.29

Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol (2008) 5.24

Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol (2006) 5.17

Resection of hepatocellular cancer ≤2 cm: results from two Western centers. Hepatology (2013) 5.05

Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Hepatology (2013) 5.03

Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology (2002) 4.83

SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression. Nature (2011) 4.57

Resection and liver transplantation for hepatocellular carcinoma. Semin Liver Dis (2005) 4.51

Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology (2009) 4.50

Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. Cancer Res (2008) 4.35

Comparative efficacy of sorafenib versus best supportive care in recurrent hepatocellular carcinoma after liver transplantation: a case-control study. J Hepatol (2013) 4.28

miR-221 overexpression contributes to liver tumorigenesis. Proc Natl Acad Sci U S A (2009) 4.15

Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology (2008) 4.03

Profiling alternative splicing on fiber-optic arrays. Nat Biotechnol (2002) 3.94

Differential allelic expression in the human genome: a robust approach to identify genetic and epigenetic cis-acting mechanisms regulating gene expression. PLoS Genet (2008) 3.92

Genome-wide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma. Hepatology (2007) 3.85

High-throughput SNP genotyping on universal bead arrays. Mutat Res (2005) 3.78

Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Res (2009) 3.77

Genomics and signaling pathways in hepatocellular carcinoma. Semin Liver Dis (2007) 3.75

Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study. J Clin Oncol (2013) 3.71

Assessment of colorectal cancer molecular features along bowel subsites challenges the conception of distinct dichotomy of proximal versus distal colorectum. Gut (2012) 3.67

Portal hypertension and the outcome of surgery for hepatocellular carcinoma in compensated cirrhosis: a systematic review and meta-analysis. Hepatology (2015) 3.63

CCR1 and CCR5 promote hepatic fibrosis in mice. J Clin Invest (2009) 3.62

Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer. J Natl Cancer Inst (2008) 3.55

Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders. Hepatology (2012) 3.54

DNA methylation signatures within the human brain. Am J Hum Genet (2007) 3.50

Focus on hepatocellular carcinoma. Cancer Cell (2004) 3.49

Decoding randomly ordered DNA arrays. Genome Res (2004) 3.49

A conditional transposon-based insertional mutagenesis screen for genes associated with mouse hepatocellular carcinoma. Nat Biotechnol (2009) 3.44

Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma. Clin Cancer Res (2012) 3.39

Epigenomic analysis detects widespread gene-body DNA hypomethylation in chronic lymphocytic leukemia. Nat Genet (2012) 3.08

Functional analysis of human microtubule-based motor proteins, the kinesins and dyneins, in mitosis/cytokinesis using RNA interference. Mol Biol Cell (2005) 3.04

Quantitative gene expression profiling in formalin-fixed, paraffin-embedded tissues using universal bead arrays. Am J Pathol (2004) 3.04

Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. J Hepatol (2012) 3.04

Management of HCC. J Hepatol (2012) 3.03

Nomenclature of the finer branches of the biliary tree: canals, ductules, and ductular reactions in human livers. Hepatology (2004) 3.00

Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin. Hepatology (2010) 3.00